Mutations in the adenomatous polyposis coli gene (APC) often cause both congenital hypertrophy of the retinal pigment epithelium (CHRPE) and familial adenomatous polyposis (FAP). To investigate the relationship between APC mutations, CHRPE and FAP, all FAP patients at the Prince of Wales Hospital, Hong Kong, were asked to participate in a study. Ten Chinese patients from 6 kindreds and their family members volunteered, along with 12 healthy control subjects selected among hospital visitors and staff. All were examined for dilated fundus by indirect ophthalmoscopy. Mutations in APC coding exons were detected by sequencing. In one FAP patient, a novel A insertion at codon 1023 was detected. Three previously reported mutations were detected in 6 FAP patients: a deletion of ACAAA at codon 1061, and 2 truncating point substitutions at codons 216 and 283. In 3 FAP patients, no APC mutation was found, suggesting that mutations in APC coding regions are not the sole cause of FAP or CHRPE. A total of 64 CHRPE lesions were found in FAP patients and some relatives with and without APC mutations. Contrary to most reports, APC mutations before exon 9 did cause CHRPE lesions, albeit relatively few.

Keywords:
Congenital hypertrophy of retinal pigment epithelium (CHRPE), Familial adenomatous polyposis (FAP)
1.
Online Mendelian Inheritance in Man, OMIM (TM). Johns Hopkins University, Baltimore, MIM 175100. Date last edited: 1/12/2001. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/.
2.
Murday V, Slack J: Inherited disorders associated with colorectal cancer. Cancer Surv 1989;8:139–157.
3.
Diaz-Llopis M, Menezo JL: Congenital hypertrophy of retinal pigment epithelium in familial adenomatous polyposis. Arch Ophthalmol 1988;106:412–413.
4.
Lyons LA, Lewis RA, Strong LC, Zuckerbrod S, Ferrell RE: A genetic study of Gardner syndrome and congenital hypertrophy of the retinal pigment epithelium. Am J Hum Genet 1988;42:290–296.
5.
Berk T, Cohen Z, McLeod RS, Parker JA: Congenital hypertrophy of the retinal pigment epithelium as a marker for familial adenomatous polyposis. Dis Colon Rectum 1988;31:253–257.
6.
Valanzano R, Cama A, Volpe R, Curia MC, Mencucci R, Palmirotta R, Battista P, Ficari F, Mariani-Costantini R, Tonelli F: Congenital hypertrophy of the retinal pigment epithelium in familial adenomatous polyposis. Cancer 1996;78:2400–2410.
7.
Polkinghorne PJ, Ritchie S, Neale K, Schoeppner G, Thomson JP, Jay BS: Pigmented lesions of the retinal pigment epithelium and familial adenomatous polyposis. Eye 1990;4:216–222.
8.
Parker JA, Berk T, Bapat BV: Familial variation in retinal pigmentation in adenomatous polyposis. Can J Ophthalmol 1995;30:138–141.
9.
Iwama T, Mishima Y, Okamoto N, Inoue J: Association of congenital hypertrophy of the retinal pigment epithelium with familial adenomatous polyposis. Br J Surg 1990;77:273–276.
10.
Moore AT, Maher ER, Koch DJ, Charles SJ: Incidence and significance of congenital hypertrophy of the retinal pigment epithelium (CHRPE) in familial adenomatous polyposis coli (FAPC). Ophthal Paediatr Genet 1992;13:67–71.
11.
Olschwang S, Tiret A, Laurent-Puig P, Muleris M, Parc R, Thomas G: Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. Cell 1993;75:959–968.
12.
Heyen F, Jagelman DG, Romania A, Zakov ZN, Lavery IC, Fazio VW, McGannon E: Predictive value of congenital hypertrophy of the retinal pigment epithelium as a clinical marker for familial adenomatous polyposis. Dis Colon Rectum 1990;33:1003–1008.
13.
Hodgson SV, Bishop DT, Jay B: Genetic heterogeneity of congenital hypertrophy of the retinal pigment epithelium (CHRPE) in families with familial adenomatous polyposis. J Med Genet 1994;31:55–58.
14.
Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589–600.
15.
Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S, Hedge P: Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665–669.
16.
Miyoshi Y, Ando H, Nagase H, Nishisho I, Horii A, Miki Y, Mori T, Utsunomiya J, Baba S, Petersen G, Hamilton SR, Kinzler KW, Vogelstein B, Nakamura Y: Germ-line mutations of APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci USA 1992;89:4452–4456.
17.
Beroud C, Soussi T: APC gene: Database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 1996;24:121–124.
18.
Armstrong JG, Davies DR, Guy SP, Frayling IM, Evans DG: APC mutations in familial adenomatous polyposis families in Northwest England. Hum Mutat 1997;10:376–380.
19.
Wallis YL, Macdonald F, Hulten M, Morton JE, McKeown CM, Neoptolemos JP, Keighley M, Morton DG: Genotype-phenotype correlation between position of constitutional APC gene mutation and CHRPE expression in familial adenomatous polyposis. Hum Genet 1994;94:543–548.
20.
Caspari R, Olschwang S, Friedl W, Mandl M, Boisson C, Boker T, Augustin A, Kadmon M, Moslein G, Thomas G: Familial adenomatous polyposis: Desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 1995;4:337–340.
21.
Bunyan DJ, Shea-Simonds J, Reck AC, Finnis D, Eccles DM: Genotype-phenotype correlations of new causative APC gene mutations in patients with familial adenomatous polyposis. J Med Genet 1995;32:728–731.
22.
Smith KJ, Johnson KA, Bryan TM, Hill DE, Markowitz S, Willson JKV, Paraskeva C, Petersen GM, Hamilton SR, Vogelstein B, Kinzler KW: The APC gene product in normal and tumor cells. Proc Natl Acad Sci USA 1993;90:2846–2850.
23.
Su LK, Johnson KA, Smith KJ, Hill DE, Vogelstein B, Kinzler KW: Association between wild type and mutant APC gene products. Cancer Res 1993;53:2728–2731.
24.
Traboulsi AI, Giardiello FM, Krush AJ, Booker GM: Pigmented ocular fundus lesions and APC mutations in familial adenomatous polyposis (Abstract No 1463). Am J Hum Genet 1995;57(supplement A252).
25.
Pack K, Smith-Ravin J, Phillips RKS, Hodgson SV: Exceptions to the rule: Individuals with FAP specific CHRPE and mutations in exon 6 of the APC gene (letter). Clin Genet 1996;50:110–111.
26.
Reck AC, Bunyan D, Eccles D, Humphry R: The presence of congenital hypertrophy of the retinal pigment epithelium in a subgroup of patients with adenomatous polyposis coli mutations. Eye 1997;11:298–300.
27.
Lam DS, Kwok SP, Kwok AK, Liew CT, Lau JW, Pang CC: Incidence and predictive value of congenital hypertrophy of retinal pigment epithelium (CHRPE) in Chinese familial adenomatous polyposis patients. Chin Med J 1998;111:278–281.
28.
Pang CP, Keung JW, Tang NL, Fan DS, Lau JW, Lam DS: Congenital hypertrophy of the retinal pigment epithelium and APC mutations in two Chinese families with familial adenomatous polyposis. Eye 2000;14:18–22.
29.
Yashima K, Nakamori S, Murakami Y, Yamaguchi A, Hayashi K, Ishikawa O, Konishi Y, Sekiya T: Mutations of the adenomatous polyposis coli gene in the mutation cluster region: Comparison of human pancreatic and colorectal cancers. Int J Cancer 1994;59:43–47.
30.
Krawczak M, Cooper DN: The Human Gene Mutation Database. Trends Genet 1997;13:121–122. http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.html.
31.
Li H, Lu S: Mutation of tumor suppressor genes APC and MCC in human esophageal cancer. Chin J Oncol 1996;17:9–12.
32.
Huang J, Zheng S, Jin S, Dunlop M: APC mutation analysis in sporadic colorectal cancer. Chin J Oncol 1996;18:415–418.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.